Conceptus — Q3 2010 Earnings Presentation
36 slides from Conceptus's earnings presentation, Oct 28, 2010
Slide 1: Conceptus Inc. Quarterly Results Third Quarter 2010
Conceptus Inc. Quarterly Results Third Quarter 2010 Exhibit 99.2 © 2010 Conceptus, Inc. All rights reserved. October 28, 2010
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements, the accuracy of which is subject to risks and uncertainties. These forward-looking statements include discussions regarding: projected net sales, net inc
Slide 3: Key Factors
Key Factors Mark Sieczkarek President and Chief Executive Officer © 2010 Conceptus, Inc. All rights reserved.
Slide 4: Summary of Q3'10
Summary of Q3’10 Steps we have taken to “control the controllable” in the current environment gained some initial traction Macro economic headwinds continue to cause considerable unpredictability in our business
Slide 5: Key Factors Remain
Key Factors Remain Macro Factor: 1. Reduced physician office visits due to economy Macro Factor: 2. Currency fluctuations Controllable Factor: 3. Physician metrics growth affected by competitor trialing
Slide 6: Status of Key Factors: Office Visits
Status of Key Factors: Office Visits Q2’10 Factors Q3’10 Impact Future Expectation 1. Reduced physician office visits Significantly unfavorable Remains unfavorable
Slide 7: Economic Drivers
Economic Drivers • Continued unemployment at 9.6% • Involuntary part-time workers up to 9.5 million, with few or no benefits • Patients losing insurance coverage (COBRA subsidies ended) or switching to Medicaid • Patients opting for high- deductible health insurance plans and health savings accounts
Slide 8: Reduced Physician Office Visits
Reduced Physician Office Visits (1) IMS Data provided by Credit Suisse Healthcare Team Domestic general physician office visits remained depressed in Q3’10 (1) . We expect this trend to continue.
Slide 9: Reduced OB/GYN Office Visits
Reduced OB/GYN Office Visits (1) IMS Data provided by Credit Suisse Healthcare Team Domestic OB/GYN office visits have declined significantly during 2010 (1) . We expect this trend to continue.
Slide 10: Status of Key Factors: Currency
Status of Key Factors: Currency Q2’10 Factors Q3’10 Impact Future Expectation 1. Reduced physician office visits Significantly unfavorable Remains unfavorable 2. Currency fluctuations Slightly favorable Dollar remains strong against euro
Slide 11: Currency: Dollar vs. Euro
Currency: Dollar vs. Euro Dollar was weaker to euro than expected in Q3’10 – Modeled exchange rate for H2’10 of $1.20 – Actual exchange rate for Q3’10 was $1.29 – Variance resulted in slight benefit in Q3’10 80% to 90% of international sales are euro denominated
Slide 12: Changes in French Reimbursement
Changes in French Reimbursement The French government has reduced physician reimbursement for hysteroscopic occlusion procedures for women under the age of 40, effective October 1, 2010 Further cost-cutting measures by the Ministry of Health are expected to affect reimbursements for medical devices
Slide 13: Status of Key Factors: Physician Metrics
Status of Key Factors: Physician Metrics Q2’10 Factors Q3’10 Impact Future Expectations 1. Reduced physician office visits Significantly unfavorable Remains unfavorable 2. Currency fluctuations Slightly favorable Dollar remains strong against euro 3. Physician metrics: shortfall due to competitor tr
Slide 14: Physician Metrics – Stabilizing in Q3
Physician Metrics – Stabilizing in Q3 In Q2’10, significant resources were allocated to defend our customer base as competitive trialing ramped, which resulted in a temporary distraction from growing the market through additional physician preceptorships, certifications and transitions to office Sin
Slide 15: Our Priorities: Control the Controllable
Our Priorities Solution Control the Controllable Solution Solution Re-deploy assets to energize market growth: “back-to-basics” strategy Accelerate growth of physician metrics including new physician adoption of Essure procedure Implement leaner cost structure through discretionary cuts
Slide 16: Back-to-Basics Solution
Back-to-Basics Solution We are one of the industry’s largest medical device sales teams dedicated to OB/GYN physicians Increased direct sales territories to better align resources Re-deployed existing sales personnel: ~160 sales personnel in the field, with ~120 in direct sales Improved ability to f
Slide 17: Third Quarter 2010 Financials
Third Quarter 2010 Financials Greg Lichtwardt Executive Vice President, Operations and Chief Financial Officer © 2010 Conceptus, Inc. All rights reserved.
Slide 18: Q3'10 Snapshot
Q3’10 Snapshot Net Sales ($mm) Gross Margin (%) Diluted Non- GAAP (2) EPS Operating Margin (%) Diluted GAAP EPS Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 $0.29 (1) $34.2 85.3% (1) 80.6% $33.9 23.4% (1) 8.1% $0.20 (1) $0.03 $0.16 Company guidance for Q3’10: Net sales: $33mm to $34mm
Slide 19: Increasing Diversification through International Sales
Worldwide Sales $28.0 (82%) $27.3 (81%) 20.3 (72%) 7.8 (28%) 19.9 (66%) 10.2 (34%) $6.6 (19%) $6.2 (18%) Increasing Diversification through International Sales The difference between dollar growth and international unit growth is primarily due to average selling price reductions due to customer mix
Slide 20: U.S. Physician Metrics
U.S. Physician Metrics Q3’10 Q2’10 Q1’09 Q4’09 Q3’09 Current Period Activity: Physicians entering preceptorship Physicians becoming certified Physicians transitioning to office Physician Base: In preceptorship 3,537 3,486 3,434 3,417 3,425 Certified and in hospital 3,267 3,128 2,956 2,793 2,848 Cert
Slide 21: Q3'10 Results
Q3’10 Q3’09 Y/Y Change Q2’10 Q/Q Change Q3’10 Results Net Sales $33.9 $34.2 (1.1 %) $36.8 (8.0%) Gross Profit Margin 80.6% 85.3% (1) nm 80.2% nm Operating Expenses $24.6 $21.2 15.9% $28.1 (12.7%) Other Income / (Expense) ($1.6) ($1.6) nm ($1.6) nm Tax Provision $0.2 $0.2 nm $0.1 100% NEAT $1.0 $6.2
Slide 22: Q3'10 GAAP vs. Non-GAAP EPS
Q3’10 GAAP vs. Non-GAAP EPS Non-GAAP EPS $0.16 Amortization of intangibles Stock-based compensation $0.03 $0.06 $0.04 Amortization of non-cash items for convertible notes $0.03 GAAP EPS See GAAP to non-GAAP reconciliation in appendix $976 $810 $1,881 $1,231 $4,898 Actual amount in $ thousands:
Slide 23: Balance Sheet
Balance Sheet Cash & cash equivalents Investments and put option (1) A/R, inventories & other current assets PP&E Intangible and other assets Goodwill Total assets ASSETS 19.3 64.0 28.2 10.4 26.2 16.4 164.5 61.7 43.5 25.7 9.8 29.1 17.3 187.1 9/30/10 A/P & other accrued ST liabilities Line of credit
Slide 24: Guidance
Guidance Q4’09A FY’09A Q4’10E FY’10E Net Sales $39 mm to $41 mm $143 mm to $145 mm $37.0 $131.4mm Gross Profit Margin 82.2% 81.1% 82.2% 81.7% Operating Expenses $22.0mm $102.5mm $22.2mm $92.7mm Net Income $8.3 mm to $9.9 mm $6.6 mm to $8.3 mm $6.6mm $7.9mm GAAP EPS (diluted) $0.26 to $0.31 $0.21 to
Slide 25: Competitive Environment & Road to Standard of Care
Competitive Environment & Road to Standard of Care Mark Sieczkarek President and Chief Executive Officer © 2010 Conceptus, Inc. All rights reserved.
Slide 26: Essure: Beats PBC Competition
Essure: Beats PBC Competition Permanent birth control failures per 1,000 women at 3 years: Essure: 1.6 (1) Tubal ligation: 9.9 (2) Vasectomy: 11.3 (3) Competitor’s procedure: 16 (4) ………………... .……… .......... ... (1) Essure Effectiveness Report (data 12/16/04) page 14 (2) Peterson, H.B., et al. The r
Slide 27: Essure: Long Term Efficacy Will Win
Essure: Long Term Efficacy Will Win Essure Competitor’s product Clinical 0 pregnancies reported 12 pregnancies reported 99.84% effective at 3 years label claim or 1 in 625 98.4% effective at 3 years label claim or 1 in 62 Commercial pregnancies reported against 465,000 procedures or 1 in 700 ? Data
Slide 28: Essure: Latest Research
Essure: Latest Research “Permanent birth control with Essure device has demonstrated to be a safe method, with low rate of complications, which its security persist(s) after 8 years follow up. That means that Essure method should be the reference method in what is to do with definitive contraception
Slide 29: Status of Competitive Trialing
Status of Competitive Trialing 7,000 total Essure accounts – 1,500 to 2,000 anticipated to trial – 800 to 900 have trialed to date Expect trialing to last 9 to 15 months if physician utilization stays steady at 1 to 2 hysteroscopic sterilization procedures per month Many mature trialing accounts hav
Slide 30: Multi-Billion Dollar Market
Multi-Billion Dollar Market Our future market: Tubal ligations (2) : 643,000 Our current addressable market “Sweet Spot” Essure: 30,000 Permanent birth control procedures each year 673,000 In millions Base of 38 million women (1) 2006-08 CDC report, Data from the National Survey of Family Growth, pu
Slide 31: Road to Standard of Care
Road to Standard of Care Future milestones: Conceptus founded EU approves Essure FDA approves Essure 6,000 hysteroscopically trained physicians Minimal patient awareness 465,000 women rely on Essure 15,000 hysteroscopically trained physicians 30% patient awareness Hysteroscopic tubal occlusion 14% o
Slide 32: Appendix
Appendix © 2010 Conceptus, Inc. All rights reserved.
Slide 33: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures The Company has supplemented its GAAP results of operations with a non-GAAP measure of net income (loss) and has supplemented its GAAP guidance with a non- GAAP measure of non-GAAP earnings per share. In each case, the non-GAAP measure excludes stock-based compensa
Slide 34: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Net income (loss), as reported $ 6,232 $ (1,665) $ 1,341 $ Adjustments to net income (loss): Amortization of intangibles (a) 2,437 Stock-based compensation (b) 1,881 1,626 5,412 4,556 Amortization of non-cash interest expense (c) 1,115 1,054 3,298 3,118 Amortization o
Slide 35: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation From To From To GAAP Guidance 0.26 $ 0.31 $ 0.21 $ 0.26 $ Estimated Non-GAAP Guidance Amortization of intangibles (a) 0.03 $ 0.03 $ 0.10 $ 0.10 $ Stock-based compensation (b) 0.06 $ 0.06 $ 0.24 $ 0.24 $ Amortization of non-cash items for convertible note (c) 0.04 $ 0.
Slide 36: Thank You
Thank You © 2010 Conceptus, Inc. All rights reserved. CC-2551 27OCT10F